Pfizer’s berobenatide data sharpen the pitch for monthly GLP-1 obesity dosing
At the American Diabetes Association meeting, Pfizer highlighted Phase 2b results for PF’3944 (berobenatide), an ultra-long-acting GLP-1 receptor agonist designed for once-monthly maintenance dosing - along with early tolerability outlines that will shape how investors weigh Pfizer’s obesity push.